Showing the single result
Filter
Midostaurin 25 mg Capsule
Midostaurin is an advanced, multi-targeted kinase inhibitor used mostly in precision oncology. It works by locking up certain abnormal proteins that help cancer cells grow and multiply. In a very direct way, it can slow down the progression of some blood and bone marrow conditions. Usually it is only given after genetic testing confirms the presence of specific target mutations, and then a prescriber confirms it is appropriate.
Therapeutic Class: Anti-neoplastics (Targeted Cancer Therapies)
Pharmacological Class: Tyrosine Kinase Inhibitor (TKI)
Available Strength: 25 mg Soft Gelatin Capsules
Prescription Status: Strictly Schedule H / Schedule G (Rx Required)
Primary Uses & Clinical Benefits
1. FLT3-Mutated Acute Myeloid Leukemia (AML)
Midostaurin is commonly used with standard induction and consolidation chemotherapy for newly diagnosed adults with Acute Myeloid Leukemia (AML), if the test is positive for a mutation in the FLT3 gene (FMS-like tyrosine kinase 3).
2. Advanced Systemic Mastocytosis (SM)
It can be prescribed as standalone monotherapy to control rare but aggressive problems where the body makes too many abnormal mast cells. This may include:
- Aggressive Systemic Mastocytosis (ASM)
- Systemic Mastocytosis with an Associated Hematological Neoplasm (SM-AHN)
- Mast Cell Leukemia (MCL)
Mechanism of Action: How It Works
Midostaurin binds to and blocks several receptor tyrosine kinases linked with cell growth and survival. In particular, it inhibits FLT3 receptor signaling, for both wild-type and mutated forms such as internal tandem duplication (ITD) and tyrosine kinase domain (TKD) variants. By shutting off these routes, it disrupts the downstream signals that support rapid white blood cell cloning.
For mastocytosis, it also blocks the c-KIT receptor tyrosine kinase, including the frequent D816V mutation variant, which pushes malignant mast cells toward apoptosis (programmed cell death). This can reduce internal organ damage caused by mast cell infiltration and can improve overall stability.
Recommended Dosage & Administration
Administration:
Take the soft gelatin capsules whole with a glass of water. Do not open, crush, break, or chew the capsule. The contents are extremely bitter, and changing the capsule shell can interfere with proper absorption.
Dietary Guidance:
Always take Midostaurin with food, whether a small meal or a fuller one. This helps reduce initial gastrointestinal irritation.
Typical Dosing Routine
For AML:
The standard dose is 50 mg (two 25 mg capsules) twice daily, at about 12-hour spacing on specific days, commonly Days 8 to 21 within each chemotherapy cycle.
For Mastocytosis (ASM/MCL):
The standard ongoing dose is 100 mg (four 25 mg capsules) twice daily, on a continuous schedule.
Vomiting Protocol:
If vomiting happens after swallowing the capsules, do not take an extra replacement dose. Just wait and take the next dose at the usual scheduled time.
Adverse Effects and Management
Because Midostaurin is often used alongside intensive chemotherapy in AML care, your oncology team typically monitors blood counts, symptoms, and vital signs very closely.
Very Common Side Effects
- Febrile Neutropenia: fever with a drop in infection-fighting white blood cells
- Gastrointestinal Distress: nausea, vomiting, mucositis (painful mouth sores), and diarrhea, which can be moderate to severe
- Systemic Pain: persistent headaches, bone pain, plus general muscle aches
- Skin Alterations: petechiae (tiny red or purple spots), bruising, localized rashes
Serious Complications (Contact Your Oncologist Immediately)
- Pulmonary Toxicity: new or worsening cough, trouble breathing, wheezing, or chest tightness, which can point toward interstitial lung disease or pneumonitis
- Cardiac Events: sudden dizziness, heart palpitations, or lightheadedness, which may suggest QT interval prolongation or a reduction in left ventricular ejection fraction
Safety Guidelines & Precautions
Risk Parameter / Clinical Status / Medical Advisory Note
Pregnancy: ❌ Contraindicated
Highly embryotoxic, can cause severe fetal injury or miscarriage. People of childbearing potential must have a negative pregnancy test before starting and use highly effective contraception during therapy, and for 4 months after the final dose.
Breastfeeding: ❌ Unsafe
Nursing should be avoided during Midostaurin treatment, and for at least 4 months after the last dose, because it may enter breast milk.
Dietary Restrictions: ❌ Avoid Grapefruit
Do not use grapefruit or grapefruit juice. Grapefruit can inhibit CYP3A4, which may raise Midostaurin blood levels too much.
Drug Interactions: ⚠️ High Risk
Avoid strong CYP3A4 inhibitors (such as ketoconazole, clarithromycin) and avoid strong inducers (such as rifampicin, phenytoin, carbamazepine), because they can greatly change the effectiveness and safety profile.
Frequently Asked Questions (FAQs)
Q. What is an FLT3 mutation, and why is testing needed before Midostaurin?
The FLT3 gene provides instructions for a protein that helps guide how bone marrow makes white blood cells. When mutated, it behaves like a stuck switch, pushing the body to continuously produce abnormal leukemia cells. Midostaurin is a targeted therapy made to block this mutated protein. It tends to be ineffective if the patient does not carry the required genetic profile, so a validated companion diagnostic test is needed first.
Q. How can I handle severe nausea with Midostaurin?
Nausea and vomiting are common, especially during the first weeks. Clinicians often prescribe preventative anti-emetic medications before your scheduled Midostaurin dose. Also, taking the capsule with a meal helps buffer your stomach lining.
Q. What if I miss a scheduled dose?
If you miss your dose, skip it and take your next dose at the regular time. Do not double up. Taking extra capsules too close together can increase toxicity risk and may worsen heart rhythm problems.
Q. How long do I stay on Midostaurin therapy?
For Acute Myeloid Leukemia (AML), Midostaurin is used in defined blocks alongside chemotherapy cycles, often across up to two cycles of induction and four cycles of consolidation.
For Advanced Systemic Mastocytosis, it is usually taken continuously for long-term maintenance, for as long as your oncologist sees clinical benefit without unacceptable side effects.